Sarepta Therapeutics, Inc. (SRPT)
SRPTNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$16.34
-0.9050 (-5.25%) today
Regular session, Nov 10, 1:38 PM ET
- Market cap
- $1.75bn
- P/E
- –
- EPS, last 4 quarters
- $-0.4600
- Dividend yield
- –
- Day range
- $16.14 to $17.59
- 52-week range
- $14.68 to $24.68
- Average volume
- 2.68m
- Previous close
- $17.24
Analysts
18 coveringHold3 buy, 11 hold, 4 sell
Targets a year out average $21.53, +31.8% from here
Earnings
next estimate $-0.3100Next report
Dec 2025
-275.7%
Mar 2026
+692.3%
Jun 2026
+23.5%
Sep 2026
-158.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $442.93m | $730.80m | $401.25m | $381.35m |
| Gross profit | $44.23m | $622.03m | $251.87m | $192.84m |
| Operating income | -$411.58m | $358.43m | $13.29m | -$9.04m |
| Net income | -$412.23m | $330.96m | -$4.89m | -$28.46m |
Last four quarters: revenue $1.96bn, margin -5.9%, free cash flow $176.40m
News
8 latest- Sarepta (SRPT) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales DeclineZacks · 4 days ago
- Sarepta Therapeutics Q3 Earnings Call HighlightsMarketBeat · 4 days ago
- Sarepta Therapeutics (SRPT) Q3 Earnings Lag EstimatesZacks · 5 days ago
- Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key MetricsZacks · 5 days ago
- Tenaya Therapeutics, Inc. (TNYA) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?Zacks · Oct 29, 2026
- Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts NearMarketBeat · Sep 15, 2026
The company
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn , X , Instagram and Facebook .
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- sarepta.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.